135 related articles for article (PubMed ID: 10470195)
1. Immunohistochemical analysis of prostate-specific antigen does not correlate to other prognostic factors in breast cancer.
Heyl W; Wolff JM; Biesterfeld S; Schröder W; Zitzelsberger D; Jakse G; Rath W
Anticancer Res; 1999; 19(4A):2563-5. PubMed ID: 10470195
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
Yu H; Levesque MA; Clark GM; Diamandis EP
Clin Cancer Res; 1998 Jun; 4(6):1489-97. PubMed ID: 9626467
[TBL] [Abstract][Full Text] [Related]
3. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.
Yu H; Giai M; Diamandis EP; Katsaros D; Sutherland DJ; Levesque MA; Roagna R; Ponzone R; Sismondi P
Cancer Res; 1995 May; 55(10):2104-10. PubMed ID: 7538047
[TBL] [Abstract][Full Text] [Related]
5. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen value as a marker in breast cancer.
Narita D; Cimpean AM; Anghel A; Raica M
Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen in breast disease.
Poh BH; Jayaram G; Sthaneshwar P; Yip CH
Malays J Pathol; 2008 Jun; 30(1):43-51. PubMed ID: 19108411
[TBL] [Abstract][Full Text] [Related]
8. [Determination of prostate-specific antigen (PSA) in cytosol of breast tumors and human endometrium--new diagnostic approaches].
Seliger E; Kaltwasser P; Röpke F
Zentralbl Gynakol; 1998; 120(4):172-5. PubMed ID: 9610520
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen (PSA) in breast and ovarian cancer.
Kucera E; Kainz C; Tempfer C; Zeillinger R; Koelbl H; Sliutz G
Anticancer Res; 1997; 17(6D):4735-7. PubMed ID: 9494598
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer.
Sauter ER; Klein G; Wagner-Mann C; Diamandis EP
Cancer Detect Prev; 2004; 28(1):27-31. PubMed ID: 15041074
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen may serve as a pathological predictor in breast cancer.
Nariţa D; Anghel A; Motoc M
Rom J Morphol Embryol; 2008; 49(2):173-80. PubMed ID: 18516323
[TBL] [Abstract][Full Text] [Related]
12. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
13. Correlation of prostate specific antigen immunoactivity (IR-PSA) to other prognostic factors in female breast cancer.
Griniatsos J; Diamantis E; Gioti J; Karyda I; Vassilopoulos PP; Agnanti N
Anticancer Res; 1998; 18(1B):683-8. PubMed ID: 9584052
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
15. Thrombomodulin is a new biological and prognostic marker for breast cancer: an immunohistochemical study.
Kim SJ; Shiba E; Ishii H; Inoue T; Taguchi T; Tanji Y; Kimoto Y; Izukura M; Takai S
Anticancer Res; 1997; 17(3C):2319-23. PubMed ID: 9216709
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk.
Sauter ER; Daly M; Linahan K; Ehya H; Engstrom PF; Bonney G; Ross EA; Yu H; Diamandis E
Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):967-70. PubMed ID: 8959318
[TBL] [Abstract][Full Text] [Related]
17. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
18. The importance of prognostic factors in premenopausal women with breast cancer.
Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
[TBL] [Abstract][Full Text] [Related]
19. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast conditions.
Nariţa D; Raica M; Anghel A; Suciu C; Cîmpean A
Rom J Morphol Embryol; 2005; 46(1):41-5. PubMed ID: 16286983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
